

BIO REFERENCE LABORATORIES INC  
Form 10-Q  
September 09, 2003

## FORM 10-Q

# SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

**ý** QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES  
EXCHANGE ACT OF 1934.

For the quarterly period ended July 31, 2003

AND

**o** TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES  
EXCHANGE ACT OF 1934

For the transition period from                      to

Commission File Number 0-15266

## BIO-REFERENCE LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

**NEW JERSEY**  
(State or other jurisdiction of  
incorporation or organization)

**22-2405059**  
(IRS Employer Identification No.)

481 Edward H. Ross Drive, Elmwood Park, NJ

07407

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

(Address of principal executive offices)

(Zip Code)

(Registrant's telephone number, including area code) **(201) 791-2600**

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

**APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY**

**PROCEEDINGS DURING THE PRECEDING FIVE YEARS**

Check whether the registrant filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities and Exchange Act of 1934 after the distribution of securities under a plan confirmed by a court.

Yes  No

**APPLICABLE ONLY TO CORPORATE ISSUERS**

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date: 11,410,883 shares of common stock (\$.01 par value) at September 5, 2003.

---

**BIO-REFERENCE, LABORATORIES, INC.**

**FORM 10-Q**

**JULY 31, 2003**

INDEX

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements  
Consolidated Balance Sheets as of July 31, 2003 (unaudited) and October 31, 2002  
  
Consolidated Statements of Operations for the  
three months and nine months ended July 31, 2003 and July 31, 2002 (unaudited)  
  
Consolidated Statements of Cash Flows for the  
nine months ended July 31, 2003 and July 31, 2002 (unaudited)  
  
Notes to consolidated financial statements (unaudited)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 4. Controls and Procedures

PART II. OTHER INFORMATION

Item 4. Submission of Matters to a Vote of Security Holders

Item 6. Exhibits and Reports on Form 8-K

Signatures

Certifications

---

**BIO-REFERENCE LABORATORIES, INC.****BALANCE SHEETS****ASSETS**

|  | <b>July 31,<br/>2003</b> | <b>October 31,<br/>2002</b> |
|--|--------------------------|-----------------------------|
|  | <b>(Unaudited)</b>       |                             |
| <b><u>CURRENT ASSETS:</u></b>  |                          |                             |
| Cash and Cash Equivalents  | \$ 3,534,074             | \$ 3,403,365                |
| Accounts Receivable (Net)  | 31,201,106               | 28,698,931                  |
| Inventory  | 1,148,938                | 1,080,768                   |
| Other Current Assets   | 252,155                  | 1,183,403                   |
| <b><u>TOTAL CURRENT ASSETS</u></b>   | <b>\$ 36,136,273</b>     | <b>\$ 34,366,467</b>        |
| <b><u>PROPERTY, PLANT AND EQUIPMENT</u></b>  | <b>\$ 6,230,941</b>      | <b>\$ 4,881,572</b>         |
| <b><u>LESS: Accumulated Depreciation</u></b>   | <b>2,646,402</b>         | <b>1,877,185</b>            |
| <b><u>TOTAL PROPERTY,<br/>PLANT AND EQUIPMENT - NET</u></b>                                    | <b>\$ 3,584,539</b>      | <b>\$ 3,004,387</b>         |
| <b><u>OTHER ASSETS:</u></b>  |                          |                             |
| Deposits   | 340,951                  | 293,203                     |
| Goodwill (Net of Accumulated Amortization of \$2,401,393)                                      | 5,843,237                | 5,843,237                   |
| Deferred Charges (Net of Accumulated Amortization of \$2,511,305 and \$2,084,614 respectively) | 2,441,532                | 2,868,222                   |
| Other Assets   | 1,039,572                | 1,066,658                   |
| <b><u>TOTAL OTHER ASSETS</u></b>   | <b>\$ 9,665,292</b>      | <b>\$ 10,071,320</b>        |
| <b><u>TOTAL ASSETS</u></b>   | <b>\$ 49,386,104</b>     | <b>\$ 47,442,174</b>        |

The Accompanying Notes are an Integral Part of These Financial Statements.

**BIO-REFERENCE LABORATORIES, INC.****BALANCE SHEETS****LIABILITIES AND SHAREHOLDERS EQUITY**

|  | <b>July 31,<br/>2003</b> | <b>October 31,<br/>2002</b> |
|--|--------------------------|-----------------------------|
|  | <b>(Unaudited)</b>       |                             |
| <b><u>CURRENT LIABILITIES:</u></b>   |                          |                             |
| Accounts Payable   | \$ 7,653,970             | \$ 6,871,331                |
| Salaries and Commissions Payable   | 2,429,436                | 2,420,274                   |
| Accrued Taxes and Expenses   | 213,360                  | 895,340                     |
| Current Portion of Long-Term Debt  |                          | 400,000                     |
| Current Portion of Leases Payable  | 700,057                  | 582,751                     |
| Notes Payable  | 9,286,547                | 10,546,010                  |
| <b><u>TOTAL CURRENT LIABILITIES</u></b>  | <b>\$ 20,283,370</b>     | <b>\$ 21,715,706</b>        |
| <b><u>LONG-TERM LIABILITIES:</u></b>   |                          |                             |
| Long-Term Portion of Leases Payable  | 1,427,368                | 1,423,659                   |
| Other Long-Term Liabilities  | 70,740                   | 95,740                      |
| <b><u>TOTAL LONG-TERM LIABILITIES</u></b>  | <b>\$ 1,498,108</b>      | <b>\$ 1,519,399</b>         |
| <b><u>COMMITMENTS AND CONTINGENCIES</u></b>  |                          |                             |
| <b><u>SHAREHOLDERS EQUITY:</u></b>   |                          |                             |
| Preferred Stock \$.10 Par Value; Authorized 1,059,589 shares, None Issued  | \$                       | \$                          |
| Series A Senior Preferred Stock, \$.10 Par Value; Authorized Issued and Outstanding 604,078 shares   | 60,408                   | 60,408                      |
| Series A - Junior Participating Preferred Stock, \$.10 Par Value, Authorized 3,000 Shares.   |                          |                             |
| Common Stock, \$.01 Par Value; Authorized 35,000,000 shares, Issued, and Outstanding 11,410,883 shares at July 31, 2003, and 11,588,583 shares at October 31, 2002 | 114,109                  | 115,886                     |
| Additional Paid-In Capital   | 27,546,154               | 28,543,576                  |
| Retained Earnings [Deficit]  | 68,353                   | (4,224,990)                 |
| <b>Totals</b>  | <b>\$ 27,789,024</b>     | <b>\$ 24,494,880</b>        |
| Deferred Compensation  | (184,398)                | (287,811)                   |
| <b><u>TOTAL SHAREHOLDERS EQUITY</u></b>  | <b>\$ 27,604,626</b>     | <b>\$ 24,207,069</b>        |
| <b><u>TOTAL LIABILITIES AND SHAREHOLDERS EQUITY</u></b>  | <b>\$ 49,386,104</b>     | <b>\$ 47,442,174</b>        |

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

The Accompanying Notes are an Integral Part of These Financial Statements.

**BIO-REFERENCE LABORATORIES, INC.****CONSOLIDATED STATEMENTS OF OPERATIONS****[UNAUDITED]**

|  | Three months ended<br>July 31, |               | Nine months ended<br>July 31, |               |
|--|--------------------------------|---------------|-------------------------------|---------------|
|  | 2003                           | 2002          | 2003                          | 2002          |
| <b><u>NET REVENUES:</u></b>                        | \$ 28,919,575                  | \$ 24,893,138 | \$ 78,629,465                 | \$ 71,051,327 |
| <b><u>COST OF SERVICES:</u></b>                    |                                |               |                               |               |
| Depreciation                                       | \$ 243,008                     | \$ 161,165    | \$ 690,538                    | \$ 426,273    |
| Employee Related Expenses                          | 6,743,758                      | 5,989,697     | 19,671,148                    | 17,500,535    |
| Reagents and Lab Supplies                          | 4,317,132                      | 3,773,726     | 12,242,583                    | 11,403,306    |
| Other Cost of Services                             | 3,037,820                      | 2,926,197     | 8,634,525                     | 9,094,981     |
| <b><u>TOTAL COST OF SERVICES</u></b>               | \$ 14,341,718                  | \$ 12,850,785 | \$ 41,238,794                 | \$ 38,425,095 |
| <b><u>GROSS PROFIT ON REVENUES</u></b>             | \$ 14,577,857                  | \$ 12,042,353 | \$ 37,390,671                 | \$ 32,626,232 |
| <b><u>General and Administrative Expenses:</u></b> |                                |               |                               |               |
| Depreciation and Amortization                      | \$ 175,850                     | \$ 184,822    | \$ 505,371                    | \$ 512,004    |
| Other General and Admin. Expenses                  | 7,750,637                      | 6,666,298     | 21,849,957                    | 18,784,503    |
| Bad Debt Expense                                   | 3,493,913                      | 3,468,547     | 9,254,382                     | 9,044,493     |
| <b><u>TOTAL GENERAL AND ADMIN. EXPENSES</u></b>    | \$ 11,420,400                  | \$ 10,319,667 | \$ 31,609,710                 | \$ 28,341,000 |
| <b><u>OPERATING INCOME</u></b>                     | \$ 3,157,457                   | \$ 1,722,686  | \$ 5,780,961                  | \$ 4,285,232  |
| <b><u>OTHER (INCOME) EXPENSES:</u></b>             |                                |               |                               |               |
| Interest Expense                                   | \$ 161,960                     | \$ 202,780    | \$ 559,901                    | \$ 721,356    |
| Interest Income                                    | (4,967)                        | (13,062)      | (18,284)                      | (31,716)      |
| <b><u>TOTAL OTHER EXPENSES - NET</u></b>           | \$ 156,993                     | \$ 189,718    | \$ 541,617                    | \$ 689,640    |
| <b><u>INCOME BEFORE TAX</u></b>                    | \$ 3,000,464                   | \$ 1,532,968  | \$ 5,239,344                  | \$ 3,595,592  |
| Provision for Income Taxes                         | 700,001                        | 28,647        | 946,000                       | 121,355       |
| <b><u>NET INCOME</u></b>                           | \$ 2,300,463                   | \$ 1,504,321  | \$ 4,293,344                  | \$ 3,474,237  |
| <b><u>NET INCOME PER SHARE - BASIC:</u></b>        | \$ .20                         | \$ .13        | \$ .37                        | \$ .31        |

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

|   |            |            |            |            |
|---|------------|------------|------------|------------|
| <u>WEIGHTED AVERAGE NUMBER OF<br/>SHARES:</u> | 11,423,483 | 11,586,003 | 11,502,016 | 11,308,204 |
|---|------------|------------|------------|------------|

|  |        |        |        |        |
|--|--------|--------|--------|--------|
| <u>NET INCOME PER SHARE - ASSUMING<br/>DILUTION:</u> | \$ .18 | \$ .12 | \$ .34 | \$ .27 |
|--|--------|--------|--------|--------|

|   |            |            |            |            |
|---|------------|------------|------------|------------|
| <u>WEIGHTED AVERAGE NUMBER OF<br/>SHARES:</u> | 12,709,076 | 13,068,750 | 12,748,984 | 12,712,045 |
|---|------------|------------|------------|------------|

The Accompanying Notes are an Integral Part of These Financial Statements.



**BIO-REFERENCE LABORATORIES, INC.****CONSOLIDATED STATEMENTS OF CASH FLOWS****[UNAUDITED]**

|   | Nine months ended<br>July 31, |                       |
|---|-------------------------------|-----------------------|
|   | 2003                          | 2002                  |
| <b><u>OPERATING ACTIVITIES:</u></b>   |                               |                       |
| Net Income  | \$ 4,293,344                  | \$ 3,474,237          |
| Adjustments to Reconcile Net Income to<br>Cash Provided by (used for) Operating Activities: |                               |                       |
| Deferred Compensation   | 103,413                       | 199,295               |
| Depreciation and Amortization   | 1,195,909                     | 938,277               |
| Provision for Bad Debts   | 9,254,382                     | 9,044,493             |
| Deferred Tax Expense (Benefit)  | 750,000                       | (27,000)              |
| Change in Assets and Liabilities:   |                               |                       |
| (Increase) Decrease in:   |                               |                       |
| Accounts Receivable   | (11,756,558)                  | (10,112,700)          |
| Inventory   | (68,170)                      | (102,240)             |
| Other Assets  | (20,662)                      | (299,023)             |
| Prepaid Expenses and Other Current Assets   | 181,248                       | (224,025)             |
| Increase (Decrease) in:   |                               |                       |
| Accounts Payable and Accrued Liabilities  | \$ 109,821                    | \$ (251,205)          |
| <b>NET CASH - OPERATING ACTIVITIES</b>  | <b>\$ 4,042,727</b>           | <b>\$ 2,640,109</b>   |
| <b><u>INVESTING ACTIVITIES:</u></b>   |                               |                       |
| Acquisition of Equipment and<br>Leasehold Improvements                                      | \$ (729,562)                  | \$ (448,168)          |
| <b>NET CASH - INVESTING ACTIVITIES</b>  | <b>\$ (729,562)</b>           | <b>\$ (448,168)</b>   |
| <b><u>FINANCING ACTIVITIES:</u></b>   |                               |                       |
| Proceeds from Exercise of Options   | \$ 70,849                     | \$ 448,204            |
| Stock Repurchase  | (1,070,048)                   |                       |
| Payments of Long-Term Debt  | (425,000)                     | (816,130)             |
| Payments of Capital Lease Obligations   | (498,793)                     | (244,849)             |
| Increase (Decrease) in Revolving Line of Credit   | \$ (1,259,466)                | (507,932)             |
| <b>NET CASH - FINANCING ACTIVITIES</b>  | <b>\$ (3,182,456)</b>         | <b>\$ (1,120,707)</b> |
| <b>NET INCREASE IN CASH</b>   | <b>\$ 130,709</b>             | <b>\$ 1,071,234</b>   |

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

|   |    |           |    |           |
|---|----|-----------|----|-----------|
| <u>CASH AT BEGINNING OF PERIODS</u>                       | \$ | 3,403,365 | \$ | 2,355,356 |
| <u>CASH AT END OF PERIODS</u>                             | \$ | 3,534,074 | \$ | 3,426,590 |
| <u>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</u> |    |           |    |           |
| Cash paid during the period for:                          |    |           |    |           |
| Interest  | \$ | 646,469   | \$ | 643,074   |
| Income Taxes  | \$ | 60,040    | \$ | 92,212    |

The Accompanying Notes are an Integral Part of These Financial Statements.

**SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:**

**(UNAUDITED)**

During the nine month period ended July 31, 2003, the Company entered into five capital leases providing for lease payments totaling approximately \$616,800, over their respective terms.

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

**BIO-REFERENCE LABORATORIES, INC.****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS****(UNAUDITED)**

[1] In the opinion of management, the accompanying unaudited consolidated financial statements reflect all adjustments [consisting only of normal adjustments and recurring accruals] which are necessary to present a fair statement of the results for the interim periods presented but do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements.

[2] The results of operations for the nine months ended July 31, 2003 are not necessarily indicative of the results to be expected for the entire year.

[3] The consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended October 31, 2002 as filed with the Securities and Exchange Commission in the Company's Annual Report on Form 10-K.

[4] The significant accounting policies followed by the Company are set forth in Note 2 to the Company's consolidated financial statements in the October 31, 2002 Form 10-K.

[5] Revenues are recognized at the time the services are performed. Revenues on the Statements of Operations are net of the following amounts for allowances and discounts.

|                   | <b>Three Months Ended<br/>July 31<br/>[Unaudited]</b> |               | <b>Nine Months ended<br/>July 31<br/>[Unaudited]</b> |               |
|-------------------|---|---------------|--|---------------|
|                   | <b>2003</b>   | <b>2002</b>   | <b>2003</b>  | <b>2002</b>   |
| Medicare/Medicaid | \$ 20,832,347   | \$ 16,817,310 | \$ 56,487,965  | \$ 47,368,546 |
| Other             | 21,784,264  | 18,261,630    | 51,855,657   | 52,248,300    |
|                   | \$ 42,616,611   | \$ 35,078,940 | \$ 108,343,622                                       | \$ 99,616,846 |

A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

[6] An allowance on the Balance Sheet for contractual credits and uncollectible accounts is determined based upon a review of the reimbursement policies and subsequent collections for the different types of payors. The aggregate allowance, which is net against accounts receivable was \$27,521,275 at July 31, 2003 and \$30,045,528 at October 31, 2002 and is comprised of the following items:

|                               | [Unaudited]<br>July 31, 2003 | October 31, 2002 |
|-------------------------------|------------------------------|------------------|
| Contractual Credits/Discounts | \$ 22,056,821                | \$ 23,010,020    |
| Doubtful Accounts             | 5,464,454                    | 7,035,508        |
|                               | \$ 27,521,275                | \$ 30,045,528    |

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

[7] The following disclosures present certain information on the Company's acquired intangible assets as of July 31, 2003 and October 31, 2002. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.

| Acquired Intangible Assets    | Weighted-Average<br>Amortization<br>Period | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net<br>Balance |
|-------------------------------|--|-----------------------------|-----------------------------|----------------|
| At July 31, 2003              |  |                             |                             |                |
| Software Costs                | 5 years                                    | 1,535,398                   | 562,682                     | 972,716        |
| Customer Lists                | 20 years                                   | 1,230,202                   | 767,715                     | 462,487        |
| Covenants not-to-Compete      | 2 years                                    | 118,760                     | 118,760                     |                |
| Employment Agreements         | 7 years                                    | 825,000                     | 499,465                     | 325,535        |
| Costs Related to Acquisitions | 19 years                                   | 1,087,471                   | 502,472                     | 584,999        |
| Patent                        | 17 Years                                   | 156,005                     | 60,210                      | 95,795         |
| <b>Totals</b>                 |  | \$ 4,952,836                | \$ 2,511,304                | \$ 2,441,532   |

| Acquired Intangible Assets    | Weighted-Average<br>Amortization<br>Period | Gross<br>Carrying<br>Amount | Accumulated<br>Amortization | Net<br>Balance |
|-------------------------------|--|-----------------------------|-----------------------------|----------------|
| At July 31, 2002              |  |                             |                             |                |
| Software Costs                | 5 years                                    | 1,535,398                   | 328,492                     | 1,206,906      |
| Customer Lists                | 20 years                                   | 1,230,202                   | 721,369                     | 508,833        |
| Covenants not-to-Compete      | 2 years                                    | 118,760                     | 118,760                     |                |
| Employment Agreements         | 7 years                                    | 825,000                     | 402,501                     | 422,499        |
| Costs Related to Acquisitions | 19 years                                   | 1,087,471                   | 460,312                     | 627,159        |
| Patent                        | 17 Years                                   | 156,005                     | 53,180                      | 102,825        |
| <b>Totals</b>                 |  | \$ 4,952,836                | \$ 2,084,614                | \$ 2,868,222   |

The aggregate acquired intangible amortization expense for the nine months ended July 31, 2003 and 2002 was approximately \$426,500. The estimated acquired intangible asset amortization expense for the fiscal year ending October 31, 2003 and for the four subsequent years is as follows:

| Fiscal Year<br>Ended<br>October 31, | Estimated<br>Amortization<br>Expense |
|-------------------------------------|--------------------------------------|
| 2003                                | 559,611                              |
| 2004                                | 547,235                              |
| 2005                                | 547,235                              |
| 2006                                | 547,235                              |
| 2007                                | 502,589                              |
|                                     | \$ 2,703,905                         |

[8] In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards [ SFAS ] No. 143 Accounting for asset retirement obligations which requires that the fair value of a liability for an asset retirement legal obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset. This statement is effective for fiscal years beginning after June 15, 2002. The Company adopted SFAS No. 143 effective November 1, 2002.

In August 2001, FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. This statement retains the requirements of SFAS No. 121 but removes goodwill from its scope and describes a probability-weighted cash flow estimation approach in evaluating possible future cash flows to be used in impairment testing. Provisions of this statement are effective for financial statements issued for fiscal years beginning after December 15, 2001, and interim periods within those fiscal years. The Company adopted SFAS No. 143 effective November 1, 2002.

In April 2002, the FASB issued SFAS No. 145, Rescission of FASB Statements No. 14, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections ( SFAS 145 ). SFAS 145 among other things rescinds SFAS No. 4, Reporting Gains and Losses from Extinguishment of Debt ( SFAS 4 ), and SFAS No. 64, Extinguishments of Debt Made to Satisfy Sinking-Fund Requirements ( SFAS 64 ) and amends SFAS No. 13, Accounting for Leases ( SFAS 13 ). This statement updates, clarifies and simplifies existing accounting pronouncements. As a result of rescinding SFAS 4 and SFAS 64, the criteria in APB No. 30, Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Event and Transactions, will be used to classify gains and losses from extinguishment of debt. SFAS 13 was amended to eliminate an inconsistency between the required accounting for sale-leaseback transactions and the required accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions and makes technical corrections to existing pronouncements. The provisions of SFAS 145 are effective for fiscal years beginning after May 15, 2002, with earlier application encouraged. The Company adopted SFAS 145 effective November 1, 2002.

In July 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities ( SFAS 146 ), which addresses the recognition, measurement, and reporting of costs associated with exit or disposal activities, and supercedes Emerging Issues Task Force ( EITF ) Issue No. 94-3, ALiability Recognition for Certain Employee Termination Benefits and other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring) ( EITF 94-3 ). The principal difference between SFAS 146 and EITF 94-3 relates to the requirements for recognition of a liability for a cost associated with an exit or disposal activity. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity, including those related to employee termination benefits and obligations under operating leases and other contracts, be recognized when the liability is incurred, and not necessarily the date of an entity's commitment to an exit plan, as under EITF 94-3. SFAS 146 also establishes that the initial measurement of a liability recognized under SFAS 146 be based on fair value. The provisions of SFAS 146 are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. The Company adopted SFAS 146 effective November 1, 2002.

In November 2002, the FASB issued Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others ( FIN 45 ). FIN 45 requires a guarantor to recognize a liability, at the inception of the guarantee, for the fair value of obligations it has undertaken in issuing the guarantee and to also include more detailed disclosures with respect to guarantees. FIN 45 is effective on a prospective basis for guarantees issued or modified starting January 1, 2003 and requires the additional disclosures in interim and annual financial statements effective for the period ended December 31, 2002. The Company's adoption of the initial recognition and measurement provisions of FIN 45 effective January 1, 2003, did not have a material impact on the Company's results of

operations or financial position.

In December 2002, FASB Statement No. 148 Accounting for Stock-Based Compensation-Transition and Disclosure was issued as an amendment of FASB Statement No. 123. Provisions of Statement No. 148 provide for alternate methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In



Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

addition, Statement No. 148 amends the disclosure requirements of Statement No. 123 to require prominent disclosure in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reporting results. Statement No. 148 is effective for entities with a fiscal year ending after December 15, 2002. Certain disclosure requirement under Statement No. 148 are effective for financial reports containing condensed financial statements for interim periods beginning after December 15, 2002. The Company adopted Statement No. 148 effective February 1, 2003.

In January 2003, the FASB issued Interpretation No. 46 ( FIN 46 ), Consolidation of Variable Interest Entities, which clarifies the application of Accounting Research Bulletin No. 51, Consolidated Financial Statements, to certain entities in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. FIN 46 is applicable immediately for variable interest entities created after January 31, 2003. For variable interest entities created prior to January 31, 2003, the provisions of FIN 46 are applicable no later than July 1, 2003. The adoption of FIN 46 has no impact on the Company at this time.

At April 30, 2003, the Company had two stock-based employee compensation plans. The Company accounts for those plans under the measurement principles of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related interpretations. No stock-based employee compensation cost is reflected in net income, as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provision of FASB Statement No. 123 to stock-based employee compensation.

|   | Three Months Ended |              | Nine Months Ended |              |
|---|--------------------|--------------|-------------------|--------------|
|   | July 31,           |              | July 31,          |              |
|   | 2003               | 2002         | 2003              | 2002         |
| <b>Net Income (Loss):</b>   |                    |              |                   |              |
| As Reported   | \$ 2,300,463       | \$ 1,504,321 | \$ 4,293,344      | \$ 3,474,237 |
| Deduct: Stock Based Employee compensation expense determined under the fair value based method-Net of Tax | -0-                | (191,296)    | (390,700)         | (1,291,118)  |
| Pro-Forma Net income  | \$ 2,300,463       | \$ 1,313,025 | \$ 3,902,644      | \$ 2,183,119 |
| <b>Basic Earnings (Loss) Per Share:</b>   |                    |              |                   |              |
| As Reported   | \$ 0.20            | \$ 0.13      | \$ 0.37           | \$ 0.31      |
| Pro-Forma   | \$ 0.20            | \$ 0.11      | \$ 0.34           | \$ 0.19      |
| <b>Diluted Earnings (Loss) Per Share:</b>   |                    |              |                   |              |
| As Reported   | \$ 0.18            | \$ 0.12      | \$ 0.34           | \$ 0.27      |
| Pro-Forma   | \$ 0.18            | \$ 0.11      | \$ 0.31           | \$ 0.17      |

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

In April 2003, the Financial Accounting Standards Board ( FASB ) issued Statement of financial Accounting Standards No. 149, Amendment of Statement 133 of Derivative Instruments and Hedging Activities ( SFAS 149 ), which clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts and for hedging activities under FASB Statement No. 133,

Accounting for Derivative Instruments and Hedging Activities. SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003.

In May 2003, the FASB issued Statement of Financial Accounting Standards No. 150, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity ( SFAS 150 ), which established standards for how an issuer classifies and measures certain financial instruments as liabilities (or assets in some circumstances) that were previously classified as equity. Financial instruments which embody an unconditional obligation requiring the issuer to redeem or repurchase it by the transfer of assets or by issuing a variable number of its equity shares must be classified as a liability. SFAS 150 is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003.

The Company expects that the adoption of the new statements will not have a significant impact on its financial statements.

[9] At July 31, 2003, the Company had recorded a net deferred tax liability of approximately \$442,000 primarily resulting from timing differences associated with the deductibility of certain accrued expenses, fixed asset depreciation and deferred cost amortization. During the nine month period ended July 31, 2003 the Company eliminated the \$900,000 valuation allowance recorded against the gross deferred tax asset at October 31, 2002. The valuation allowance recorded at October 31, 2002 principally pertained to net operating loss carryforwards which management estimates will be fully utilized in fiscal 2003.

[10] In January 2002, we amended our revolving loan agreement with PNC Bank. The maximum amount of the credit line available to the Company is now the lesser of (i) \$25,000,000 or (ii) 50% of our qualified accounts receivable (as defined in the agreement). Interest on advances will be subject to the prime rate or Eurodollar rate of interest plus an additional interest percentage. The additional interest percentage charges on borrowings range from 1% to 3% and are determined based upon certain financial ratios achieved by the Company. During the current fiscal period, the Company had elected to have \$8,000,000 of the total advances outstanding converted into a Eurodollar rate loan with a variable interest rate of 2.740% at July 31, 2003. The remaining outstanding advances during that period were subject to the prime rate of interest. At July 31, 2003, advances of \$1,286,546 were subject to interest at the prime rate. The credit line is collateralized by substantially all of our assets and the assignment of a \$4,000,000 insurance policy on the life of the president of our Company. The line of credit is currently available through September 2004. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, various financial ratios and insurance coverage. As of July 31, 2003, we were utilizing approximately \$9,287,000 of this credit facility and had approximately \$11,080,000 of available unused credit under this revolving loan agreement.

[11] In March 2003, the Board of Directors approved the repurchase of up to 500,000 shares of the Company's common stock in the over-the-counter market on or before October 31, 2004 provided: (1) all such repurchases and bids to repurchase effected on any given day shall be made only through a single broker or dealer on that day; (2) any such repurchases on a given day shall not be the opening transaction reported to the consolidated transaction reporting system and no repurchases shall be made during the last half-hour before the scheduled close of trading; (3) the highest purchase price paid to repurchase any shares shall not exceed the higher of the highest independent bid or the last independent reported sale price; and (4) the maximum number of shares that can be repurchased on a given day (excluding block repurchases) shall not exceed 25% of the average daily trading volume reported for the four calendar weeks preceding

the week in which the repurchase is made. It was further decided, that periodically after the repurchase, the repurchased shares would be retired and canceled.

As of July 31, 2003, the Company had repurchased a total of 229,700 shares of its common stock at a cost of \$1,070,048. The cost of the repurchased shares of common stock has been recorded as a reduction of common stock in the amount of \$2,297 and a reduction of additional paid-in capital in the amount of \$1,067,751.

[12] In the normal course of its business, the Company is exposed to a number of asserted and unasserted potential claims. In the opinion of management, the resolution of these matters will not have a material adverse effect on the Company's financial position or results of operations.

At November 1, 1998, the Company was being represented by counsel in connection with various reviews being conducted by the Company's Medicare carrier. One review involved overpayments that occur in the normal course of business. The Company remitted approximately \$75,000 to Medicare in connection with this matter. At October 31, 2002, the Company had established a reserve of \$154,000 on its financial statements for the remaining liability. In January 2003, Medicare determined that the remaining overpayment was \$78,684 and interest on this amount was \$2,392. The total amount of \$81,076 was remitted by the Company to Medicare in January 2003, bringing the matter to a close.

In April 2003, a Determination was rendered in a lawsuit filed by a former employee, David Bennett, who alleged that his employment contract had been improperly terminated by the Company. The arbitrator who presided at the hearing concluded that Mr. Bennett's employment was duly terminated by the Company for cause and rendered his Determination in favor of the Company and against David Bennett with respect to all of Mr. Bennett's claims.

Item 2.

**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

Note Regarding Forward-Looking Statements

**This Quarterly Report on Form 10-Q contains historical information as well as forward-looking statements. Statements looking forward in time are included in this Quarterly Report pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to be materially different from any future performance suggested herein. For a further discussion concerning risks to the Company's business, the results of its operations and its financial condition, reference is made to the Company's Annual Report on Form 10-K for the year ended October 31, 2002.**

OVERVIEW:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of revenues and expenses during the reporting period. While many aspects of our business are subject to complex federal, state and local regulations, the accounting for our business is generally straightforward. Our revenues are primarily comprised of a high volume of relatively low dollar transactions, and about half of all our costs consist of employee compensation and benefits. Revenues are recognized at the time the services are performed and are reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered including prospectively determined adjustments under reimbursement agreements with third-party payors. These adjustments are accrued on an estimated basis in the period the services are rendered and adjusted in future periods as final settlements are determined. These estimates are reviewed and adjusted, if warranted, by senior management on a monthly basis. We believe that our estimates and assumptions are correct; however, several factors could cause actual results to differ materially from those currently anticipated due to a number of factors:

our failure to integrate newly acquired businesses (if any) and the cost related to such integration.

our failure to obtain and retain new customers and alliance partners, or a reduction in tests ordered or specimens submitted by existing customers.

adverse results from investigations of clinical laboratories by the government, which may include significant monetary damages and/or exclusion from the Medicare and Medicaid programs.

loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of CLIA-88, or those of Medicare, Medicaid or other federal, state or local agencies.

future changes in federal, state, local and third party payor regulations or policies (or in the interpretation of current regulations) affecting governmental and third-party reimbursement for clinical laboratory testing.

failure to comply with the Federal Occupational Safety and Health Administration requirements and the recently passed Needlestick Safety and Prevention Act.

failure to comply with HIPAA, which could result in significant fines as well as substantial criminal penalties.

changes in payor mix.

failure to maintain our days sales outstanding levels.

increased competition, including price competition.

our ability to attract and retain experienced and qualified personnel.

adverse litigation results.

We utilize diluted earnings per share ( EPS ) on pre-tax income as a performance indicator rather than the traditional EPS calculation on an after tax basis. This pre-tax EPS takes out the nuance of tax differences caused by large net operating loss carryforwards which create benefits (which we used in the past) and tax expense (which we expect in the future). Our pre-tax EPS on a fully diluted basis is shown below:

|         | January 31 | Three Months Ended<br>April 30 | July 31 | July 31 | Nine Months Ended<br>July 31 |
|---------|------------|--------------------------------|---------|---------|------------------------------|
| FY 2002 | .06        | .10                            | .12     | .28     |                              |
| FY 2003 | .04        | .13                            | .24     | .41     |                              |

COMPARISON OF THIRD QUARTER 2003 VS THIRD QUARTER 2002

NET REVENUES:

Net revenues for the three month period ended July 31, 2003 were \$28,919,575 as compared to \$24,893,138 for the three month period ended July 31, 2002; which represents an 16% increase in net revenues. This increase is due to a 9% increase in patient counts and a 7% increase in net revenues per patient.

The number of patients serviced during the three month period ended July 31, 2003 was 547,568 which was 9% greater when compared to the prior fiscal year's three month period. Net revenue per patient for the three month period ended July 31, 2003 was \$52.63 compared to net revenue per patient of \$49.38 for the three month period ended July 31, 2002, an increase of \$3.25 or 7%. This increase in net revenues per patient is directly related to the increase in more expensive and esoteric testing.

COST OF SALES:

Cost of Sales increased from \$12,850,785 for the three month period ended July 31, 2002 to \$14,341,718 for the three month period ended July 31, 2003, an increase of \$1,490,933 or 12%. This increase is in line with the increase in net revenues of 16%.

GROSS PROFITS:

Gross profits, increased from \$12,042,353 for the three month period ended July 31, 2002 to \$14,577,857 for the three month period ended July 31, 2003; an increase of \$2,535,504 or 21%. This is primarily attributable to the increase in net revenues. Profit margins increased from 48% to 50% which is primarily attributable to the increase in net revenues and the decrease in direct costs relative to the increase in net revenues.

GENERAL AND ADMINISTRATIVE EXPENSES:

General and administrative expenses for the three month period ended July 31, 2002 was \$10,319,667 as compared to \$11,420,400 for the three month period ended July 31, 2003, an increase of \$1,100,733 or 11%. This increase is in line with the increase in net revenues. However, insurance expense increased approximately \$308,000 or 124% over the prior comparable period.

INTEREST EXPENSE:

Interest expense decreased to \$161,960 during the three month period ended July 31, 2003 from \$202,780 during the three month period ended July 31, 2002 and is due to our decrease in asset based borrowing of approximately \$1,259,000 and lower interest rates. We believe that this trend will continue during the remainder of the current fiscal year.



INCOME:

We realized net income of \$2,300,463 for the three month period ended July 31, 2003, as compared to \$1,504,321 for the three month period ended July 31, 2002 an increase of 53%. Pre-tax income for the period ended July 31, 2003 was \$3,000,464 compared to \$1,532,968 for the period ended July 31, 2002, an increase of \$1,467,496 (96%). The provision for income taxes increased from \$28,647 for the period ended July 31, 2002 to \$700,001 for the period ended July 31, 2003. This increase was anticipated due to the full utilization of certain state tax loss carry-forwards in fiscal 2002 and Federal and State tax loss carry-forwards during the third quarter of fiscal 2003.

NINE MONTHS 2003 COMPARED TO NINE MONTHS 2002

NET REVENUES:

Net Revenues for the nine month period ended July 31, 2003 were \$78,629,465 as compared to \$71,051,327 for the nine month period ended July 31, 2002; this represents an 11% increase in net revenues. This increase is due to a 7% increase in patient counts and a 4% increase in revenue per patient.

The number of patients serviced during the nine month period ended July 31, 2003 was 1,530,727 which was 7% greater when compared to the prior fiscal year's nine month period. Net revenue per patient for the nine month period ended July 31, 2003 was \$51.19, compared to net revenue per patient for the nine month period ended July 31, 2002 of \$49.43, an increase of \$1.76 or 4%. This increase is directly related to our increase in more expensive and esoteric testing.

COST OF SALES:

Cost of Sales increased to \$41,238,794 for the nine month period ended July 31, 2003 from \$38,425,095 for the nine month period ended July 31, 2002. This amounts to a \$2,813,699 or 7% increase in direct operating costs. This increase is less than the increase in net revenues of 11%.

GROSS PROFITS:

Gross profits on net revenues, increased to \$37,390,671 for the nine month period ended July 31, 2003 from \$32,626,232 for the nine month period ended July 31, 2002; an increase of \$4,764,439 (15%) primarily attributable to the increase in net revenues. Gross profit margins increased to 48% during the nine month period ended July 31, 2003, as compared to 46% for the nine month period ended July 31, 2002, primarily attributable to operating efficiencies realized in regard to the increase in net revenues.

GENERAL AND ADMINISTRATIVE EXPENSES:

General and administrative expenses for the nine month period ended July 31, 2003 were \$31,609,710 as compared to \$28,341,000 for the nine month period ended July 31, 2002, an increase of \$3,268,710 or 12%. This increase is in line with the increase in net revenues. However, insurance expense increased approximately \$931,000 or 141% over the prior comparable period.

INTEREST EXPENSE:

Interest expense decreased to \$559,901 during the nine month period ended July 31, 2003 as compared to \$721,356 during the nine month period ended July 31, 2002, a decrease of \$161,455 and is due to our decrease in asset based borrowing and lower interest rates. We believe that this trend will continue during the remainder of the current fiscal year.

INCOME:

We realized net income of \$4,293,344 for the nine months ended July 31, 2003 as compared to \$3,474,237 for the nine month period ended July 31, 2002. Pre-tax income for the period ended July 31, 2003 was \$5,239,344, as compared to \$3,595,592 for the period ended July 31, 2002, an increase of \$1,643,752 (46%) and was caused primarily by a decrease in expenses in relation to an increase in net revenues. The provision for income taxes increased from \$121,355 for the period ended July 31, 2002, to \$946,000 for the current nine month period. This increase was anticipated due to the full utilization of certain state tax loss carry-forwards in fiscal 2002 and Federal and State tax loss carry-forwards during the third quarter of fiscal 2003.

LIQUIDITY AND CAPITAL RESOURCES:

Our working capital at July 31, 2003 was approximately \$15,853,000 as compared to approximately \$12,651,000 at October 31, 2002, an increase of approximately \$3,452,000. Our cash position increased by approximately \$131,000 during the current period. We decreased our short term debt by approximately \$1,259,000 and repaid approximately \$924,000 in existing long-term debt and capital lease obligations. We had current liabilities of approximately \$20,283,000 at July 31, 2003. We generated approximately \$4,043,000 in cash from operations during the current nine month period, compared to cash from operations for the nine month period ended July 31, 2002 of approximately \$2,640,000.

As of July 31, 2003, the Company had repurchased a total of 229,700 shares of its common stock at a cost of \$1,070,048. The cost of the repurchased shares of common stock has been recorded as a reduction of common stock in the amount of \$2,297 and a reduction of additional paid-in capital in the amount of \$1,067,751.

Accounts receivable, net of allowance for doubtful accounts, totaled approximately \$31,201,000 at July 31, 2003, an increase of approximately \$2,502,000 from October 31, 2002, or 9%. This increase was primarily attributable to increased revenue. Cash collected during the nine month period ended July 31, 2003 increased 9% over the comparable nine month period.

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the client base. We have significant receivable balances with government payors and various insurance carriers. Generally, we do not require collateral or other security to support customer receivables, however, we continually monitor and evaluate our client acceptance and collection procedures to minimize potential credit risks associated with our accounts receivable. While we maintain what we believe to be an adequate allowance for doubtful accounts, there can be no assurance that our ongoing review of accounts receivable will not result in the need for additional reserves. Such additional reserves could have a material impact on our financial position and results of operations.

In January 2002, we amended our revolving loan agreement with PNC Bank. The maximum amount of the credit line available to the Company is now the lesser of (i) \$25,000,000 or (ii) 50% of our qualified accounts receivable (as defined in the agreement). Interest on advances will be subject to the prime rate or Eurodollar rate of interest plus an additional interest percentage. The additional interest percentage charges on borrowings range from 1% to 3% and are determined based upon certain financial ratios achieved by the Company. During the current fiscal period, the Company had elected to have \$8,000,000 of the total advances outstanding converted into a Eurodollar rate loan with a variable interest rate of 2.740% at July 31, 2003. The remaining outstanding advances during that period were subject to the prime rate of interest. At July 31, 2003, advances of \$1,286,546 were subject to interest at the prime rate. The credit line is collateralized by substantially all

of our assets and the assignment of a \$4,000,000 insurance policy on the life of the president of our Company. The line of credit is currently available through September 2004. The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, various financial ratios and insurance coverage. As of July 31, 2003, we were utilizing approximately \$9,287,000 of this credit facility and had approximately \$11,080,000 of available unused credit under this revolving loan agreement.

We intend to expand our laboratory operations through aggressive marketing, developing specialty testing areas and through acquisitions. These acquisitions may involve cash, notes, common stock, and/or combinations thereof.

At November 1, 1998, the Company was being represented by counsel in connection with various reviews being conducted by the Company's Medicare carrier. One review involved overpayments that occur in the normal course of business. The Company remitted approximately \$75,000 to Medicare in connection with this matter. At October 31, 2002, the Company had established a reserve of \$154,000 on its financial statements for the remaining liability. In January 2003, Medicare determined that the remaining overpayment was \$78,684 and interest on this amount was \$2,392. The total amount of \$81,076 was remitted by the Company to Medicare in January 2003, bringing the matter to a close.

We have various employment and consulting agreements with commitments totaling approximately \$6,282,000 over the next five years of which approximately \$2,968,000 is due during fiscal 2003. We have capitalized leases with commitments totaling approximately \$2,006,000 of which approximately \$748,000 is due during fiscal 2003. We have operating leases with commitments totaling approximately \$9,380,000 of which approximately \$3,444,000 is due during fiscal 2003.

Our cash balance at July 31, 2003 totaled approximately \$3,534,000 as compared to approximately \$3,403,000 at October 31, 2002. We believe that our cash position, the anticipated cash generated from future operations, and the availability of our credit line with PNC Bank, will meet our anticipated cash needs in fiscal 2003.

Impact of Inflation - To date, inflation has not had a material effect on our operations.

#### New Authoritative Pronouncements

The Financial Accounting Standards Board ( FASB ) has issued Statement No. 143 Accounting for Asset Retirement Obligations in June 2001, which requires that the fair value of a liability for an asset retirement legal obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. The associated asset retirement costs are capitalized as part of the carrying amount of the long-lived asset. This statement is effective for fiscal years beginning after June 15, 2002. The Company has adopted SFAS No. 143 effective November 1, 2002.

In August 2001, FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. This statement retains the requirements of SFAS No. 121 but removes goodwill from its scope and describes a probability-weighted cash flow estimation approach in evaluating possible future cash flows to be used in impairment testing. Provisions of this statement are effective for financial statements issued for fiscal years beginning after December 15, 2001, and interim periods within those fiscal years. The Company has adopted SFAS No. 144 effective November 1, 2002.

In April 2002, the FASB issued SFAS No. 145, Rescission of FASB Statements No. 14, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections ( SFAS 145 ). SFAS 145 among other things rescinds SFAS No. 4,

Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

Reporting Gains and Losses from Extinguishment of Debt ( SFAS 4 ), and SFAS No. 64, Extinguishments of Debt Made to Satisfy Sinking-Fund Requirements ( SFAS 64 ) and amends SFAS No. 13, Accounting for Leases ( SFAS 13 ). This statement updates, clarifies and simplifies existing accounting pronouncements. As a result of rescinding SFAS 4 and SFAS 64, the criteria in APB No. 30, Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Event and Transactions, will be used to classify gains and losses from extinguishment of debt. SFAS 13 was amended to eliminate an inconsistency between the required accounting for sale-leaseback transactions and the required accounting for certain lease modifications that have economic effects that are similar to sale-leaseback transactions and makes technical corrections to existing pronouncements. The provisions of SFAS 145 are effective for fiscal years beginning after May 15, 2002, with earlier application encouraged. The Company adopted SFAS 145 effective November 1, 2002.

In July 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities ( SFAS 146 ), which addresses the recognition, measurement, and reporting of costs associated with exit or disposal

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

activities, and supercedes Emerging Issues Task Force ( EITF ) Issue No. 94-3, Liability Recognition for Certain Employee Termination Benefits and other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring) ( EITF 94-3 ). The principal difference between SFAS 146 and EITF 94-3 relates to the requirements for recognition of a liability for a cost associated with an exit or disposal activity. SFAS 146 requires that a liability for a cost associated with an exit or disposal activity, including those related to employee termination benefits and obligations under operating leases and other contracts, be recognized when the liability is incurred, and not necessarily the date of an entity's commitment to an exit plan, as under EITF 94-3. SFAS 146 also establishes that the initial measurement of a liability recognized under SFAS 146 be based on fair value. The provisions of SFAS 146 are effective for exit or disposal activities that are initiated after December 31, 2002, with early application encouraged. The Company adopted SFAS 146 effective November 1, 2002.

In November 2002, the FASB issued Interpretation No. 45, Guarantor's Accounting and Disclosure Requirements for Guarantees, Including Indirect Guarantees of Indebtedness of Others ( FIN 45 ). FIN 45 requires a guarantor to recognize a liability, at the inception of the guarantee, for the fair value of obligations it has undertaken in issuing the guarantee and to also include more detailed disclosures with respect to guarantees. FIN 45 is effective on a prospective basis for guarantees issued or modified starting January 1, 2003 and requires the additional disclosures in interim and annual financial statements effective for the period ended December 31, 2002. The Company's adoption of the initial recognition and measurement provisions of FIN 45 effective January 1, 2003, did not have a material impact on the Company's results of operations or financial position.

In December 2002, FASB Statement No. 148 Accounting for Stock-Based Compensation-Transition and Disclosure was issued as an amendment of FASB Statement No. 123. Provisions of Statement No. 148 provide for alternate methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, Statement No. 148 amends the disclosure requirements of Statement No. 123 to require prominent disclosure in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reporting results. Statement No. 148 is effective for entities with a fiscal year ending after December 15, 2002. Certain disclosure requirement under Statement No. 148 are effective for financial reports containing condensed financial statements for interim periods beginning after December 15, 2002. The Company adopted Statement No. 148 effective February 1, 2003.

In January 2003, the FASB issued Interpretation No. 46 ( FIN 46 ), Consolidation of Variable Interest Entities, which clarifies the application of Accounting Research Bulletin No. 51, Consolidated Financial Statements, to certain entities in which equity investors do not have the characteristics of a controlling financial interest or do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties. FIN 46 is applicable immediately for variable interest entities created after January 31, 2003. For variable interest entities created prior to January 31, 2003, the provisions of FIN 46 are applicable no later than July 1, 2003. The adoption of FIN 46 has no impact on the Company at this time.

In April 2003, the Financial Accounting Standards Board ( FASB ) issued Statement of financial Accounting Standards No. 149, Amendment of Statement 133 of Derivative Instruments and Hedging Activities ( SFAS 149 ), which clarifies financial accounting and reporting for derivative instruments, including certain derivative instruments embedded in other contracts and for hedging activities under FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities. SFAS No. 149 is effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003.

In May 2003, the FASB issued Statement of Financial Accounting Standards No. 150, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity ( SFAS 150 ), which established standards for how an issuer classifies and measures certain financial instruments as liabilities (or assets in some circumstances) that were previously classified as equity. Financial instruments which

## Edgar Filing: BIO REFERENCE LABORATORIES INC - Form 10-Q

embody an unconditional obligation requiring the issuer to redeem or repurchase it by the transfer of assets or by issuing a variable number of its equity shares must be classified as a liability. SFAS 150 is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003.



The Company expects that the adoption of the new statements will not have a significant impact on its financial statements.

**Item 4 CONTROLS AND PROCEDURES**

(a) Explanation of disclosure controls and procedures. The Company's chief executive officer and its chief financial officer after evaluating the effectiveness of the Company's disclosure controls and procedures (as defined in Exchange Act Rules 13a-14(c) and 15-d-14(c) as of a date within 90 days of the filing date of the quarterly report (the Evaluation Date) have concluded that as of the Evaluation Date, the Company's disclosure controls and procedures were adequate and effective to ensure that material information relating to the Company and its consolidated subsidiaries would be made known to them by others within those entities, particularly during the period in which this quarterly report was being prepared.

(b) Changes in internal controls. There were no significant changes in the Company's internal controls or in other factors that could significantly affect the Company's disclosure controls and procedures subsequent to the Evaluation Date, nor any significant deficiencies or material weaknesses in such disclosure controls and procedures requiring corrective actions. As a result, no corrective actions were taken.

**BIO-REFERENCE LABORATORIES, INC.**

**PART II - OTHER INFORMATION**

**Item 4 Submission of Matters to a Vote of Security Holders**

Our Annual Meeting of Stockholders was held on July 31, 2003. At the meeting, the following two individuals were elected by the following vote to serve as Class III directors, each for a term of three years and until his successor is duly elected and qualified.

|               | <b>For</b> | <b>Withheld</b> |
|---------------|------------|-----------------|
| Gary Lederman | 11,439,289 | 134,095         |
| John Roglieri | 11,439,289 | 134,095         |

Our other directors whose term continued are as follows:

|                  |                   |
|------------------|-------------------|
| Marc D. Grodman  | Class I director  |
| Howard Dubinett  | Class I director  |
| Sam Singer       | Class II director |
| Morton L. Topfer | Class II director |

The proposal to amend the Corporation's Certificate of Incorporation to increase the number of authorized shares of Common Stock, \$.01 par value, from 18,333,333 shares to 35,000,000 was approved; for 11,178,575, against 385,777, abstentions 8,932.

The proposal to ratify the adoption of the 2003 Employee Incentive Stock Option Plan was approved; for 6,718,199, against 352,877, abstentions 25,790, broker non votes 4,477,002.

**Item 6 Exhibits and Reports on Form 8-K**

(a) Exhibits:

31.1 - Certification of Chief Executive Officer

31.2 - Certification of Chief Financial Officer

32.1 - Certification Pursuant to 18 U.S.C. Section 1350 of Chief Executive Officer

32.2 - Certification Pursuant to 18 U.S.C. Section 1350 of Chief Financial Officer

(b) Reports on Form 8-K - The Company filed no reports on Form 8-K during the quarter ended July 31, 2003.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BIO-REFERENCE LABORATORIES, INC.**  
**(Registrant)**

/S/ Marc D. Grodman  
Marc D. Grodman, M.D.  
President and Chief Executive Officer

/S/ Sam Singer  
Sam Singer  
Chief Financial and Accounting Officer

Date: September 5, 2003.